Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGFÃ TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
IPO Year: 2000
Exchange: NASDAQ
Website: agenusbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/4/2025 | $25.00 | Neutral → Buy | H.C. Wainwright |
| 7/19/2024 | $35.00 → $8.00 | Outperform → Neutral | Robert W. Baird |
| 7/18/2024 | Outperform → Mkt Perform | William Blair | |
| 7/18/2024 | $9.00 | Buy → Neutral | H.C. Wainwright |
| 6/6/2023 | $8.00 | Outperform | Robert W. Baird |
| 6/6/2023 | $60.00 → $80.00 | Outperform | Robert W. Baird |
| 2/28/2023 | $8.00 | Buy | H.C. Wainwright |
| 9/28/2022 | $5.00 | Outperform | SMBC Nikko |
| 3/2/2022 | $12.00 → $14.00 | Buy | HC Wainwright & Co. |
| 12/16/2021 | $12.00 | Buy | HC Wainwright & Co. |
Agenus Inc. (NASDAQ:AGEN) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BAL) combination achieved a two-year survival rate of 42% along with a now more mature 21-month median overall survival (OS) in an expanded cohort of 123 patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases (NLM). Agenus also confirmed that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the design of the global BATTMAN Phase 3 trial. The FDA waived the need for a BOT monotherapy arm, allowing for a simple two-arm study design. These new BOT/BAL data were reported at the 2025 ESMO Ga
Partnership aims to accelerate precision immunotherapy by leveraging AI-powered virtual cell models to identify which patients are most likely to benefit from BOT/BAL treatment Collaboration builds on landmark 2024 Cancer Discovery study elucidating botensilimab's unique FcγR-mediated immune activation underlying activity in refractory tumors Supports AI-enabled biomarker discovery, aligning with the national priorities and the FDA to expand access to personalized cancer treatment Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive biomark
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2025 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests. Webcast Information: Date: Tuesday, June 17, 2025 Time: 10:30 a.m. ET A live webcast and replay
The acquisition will establish Zydus' presence in fast growing global biologics CDMO space. Acquired capabilities include cutting-edge biologics development and manufacturing services to serve the needs of global innovative biotechnology companies. AHMEDABAD, India and PENNINGTON, N.J., June 3, 2025 /PRNewswire/ -- Zydus Lifesciences Ltd. (including its subsidiaries/affiliates, hereafter referred to as 'Zydus' today announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s (NASDAQ:AGEN) U.S.-based biologics CMC facilities. This acquisition marks Zydus' strategic investment in U.S.-based manufact
$75M upfront payment to Agenus for the transfer of manufacturing assets $50M of contingent payments to Agenus Exclusive license for BOT/BAL in India and Sri Lanka $16M equity investment at $7.50 per share Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as "Zydus," designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL). The strategic collaboration includes an exchange of Agenus' state-of-the-art biologics
Study shows botensilimab "switches on" the body's own T-cells to attack a common, treatment-resistant form of colorectal cancer Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable (MSS), or mismatch repair proficient (pMMR), metastatic colorectal cancer (mCRC)—a tumor type traditionally resistant to immunotherapy and representing approximately 85-95% of all colorectal cancers. T cells are key immune cells capable of recognizing and attacking
Presenting new data in the most mature readout to date, with 60% more patients and reported median and 2-year overall survival. Agenus Inc. ("Agenus" or the Company") (NASDAQ:AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Barcelona, Spain. A poster presentation will feature updated findings from an expanded cohort of 123 patients, incorporating additional participants and extended follow-up to further assess clinical activ
BOT/BAL Achieves Breakthrough Response Rates in MSS Cancers — Oral AACR Data Spotlight Pan-Tumor Neoadjuvant Success Seasoned Leader Onboard to Accelerate BOT/BAL Toward Registration Milestones Near-Term Capital Transaction Poised to Bolster Liquidity Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program. "The growing strength of our BOT/BAL data across multiple hard-to-treat cancers reinforces our conviction in its transformative potential and
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation today announced that Dr. Richard M. Goldberg, an internationally recognized expert in gastrointestinal (GI) cancer treatment and research, has joined the company as Chief Development Officer. In this role, Dr. Goldberg will lead efforts to advance the botensilimab/balstilimab (BOT/BAL) program for patients and guide the company's regulatory and development strategy as it prepares to re-engage global health authorities. Dr. Goldberg's distinguished career spans over four decades, during which he has made significant contributions to oncology through clinical practice, research, and leadership. "Five years ago, I stepped awa
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/903911751. About Agenus Agenu
H.C. Wainwright upgraded Agenus from Neutral to Buy and set a new price target of $25.00
Robert W. Baird downgraded Agenus from Outperform to Neutral and set a new price target of $8.00 from $35.00 previously
William Blair downgraded Agenus from Outperform to Mkt Perform
H.C. Wainwright downgraded Agenus from Buy to Neutral and set a new price target of $9.00
Robert W. Baird initiated coverage of Agenus with a rating of Outperform and set a new price target of $8.00
Robert W. Baird initiated coverage of Agenus with a rating of Outperform and set a new price target of $80.00 from $60.00 previously
H.C. Wainwright resumed coverage of Agenus with a rating of Buy and set a new price target of $8.00
SMBC Nikko initiated coverage of Agenus with a rating of Outperform and set a new price target of $5.00
HC Wainwright & Co. reiterated coverage of Agenus with a rating of Buy and set a new price target of $14.00 from $12.00 previously
HC Wainwright & Co. initiated coverage of Agenus with a rating of Buy and set a new price target of $12.00
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
8-K - AGENUS INC (0001098972) (Filer)
DEFR14A - AGENUS INC (0001098972) (Filer)
8-K - AGENUS INC (0001098972) (Filer)
EFFECT - AGENUS INC (0001098972) (Filer)
S-3 - AGENUS INC (0001098972) (Filer)
10-Q - AGENUS INC (0001098972) (Filer)
8-K - AGENUS INC (0001098972) (Filer)
DEFR14A - AGENUS INC (0001098972) (Filer)
DEF 14A - AGENUS INC (0001098972) (Filer)
PRE 14A - AGENUS INC (0001098972) (Filer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)
Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran
Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.
Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer Immuno-oncology leader, Agenus Inc. ("Agenus") (NASDAQ:AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Ta
BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballantyne as the Company's Chief Financial Officer, effective immediately. Mr. Ballantyne succeeds Salvatore Calabrese, who is expected to remain employed by the Company for a reasonable transition period to enable an orderly transition of duties. "I am thrilled to be joining the Gain team at this exciting time in the Company's development," said Mr. Ballantyne, Chief Financial Officer. "Gain's lead program with disease-modifyi
Patricia Carlos named Chief Regulatory, Quality, and Safety OfficerTodd Yancey, MD named Senior Global Clinical Development, Medical Affairs and Commercial Advisor LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the appointment of Patricia Carlos as Chief Regulatory, Quality, and Safety Officer; Todd Yancey, MD as Global Clinical Development, Medical Affairs and Commercial Development Advisor. "Our upcoming worldwide Phase 2 botensilimab "ACTIVATE" programs in MSS colorectal cancer and metastatic melanoma are
Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has elected Manuel Hidalgo Medina, M.D., Ph.D., to the Board, effective June 1, 2021. Dr. Hidalgo will serve as a member of the Science & Technology Committee of the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005285/en/Chief of the Division of Hematology and Medical Oncology, Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center (Photo: Business Wire) "We are delighted to welcome Manny to our Board of Directors," said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appointment of Andy Hurley as its Chief Commercial Officer. “We welcome Andy Hurley as we transition into a commercial stage company with a robust research and clinical pipeline,” said Garo Armen, PhD, Chairman and CEO of Agenus. “Andy’s experience and passion in successfully commercializing biopharmaceutical agents and his excitement about our portfolio made him a natural fit to join our team.” "I am excited
$75M upfront payment to Agenus for the transfer of manufacturing assets $50M of contingent payments to Agenus Exclusive license for BOT/BAL in India and Sri Lanka $16M equity investment at $7.50 per share Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as "Zydus," designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL). The strategic collaboration includes an exchange of Agenus' state-of-the-art biologics
BOT/BAL Achieves Breakthrough Response Rates in MSS Cancers — Oral AACR Data Spotlight Pan-Tumor Neoadjuvant Success Seasoned Leader Onboard to Accelerate BOT/BAL Toward Registration Milestones Near-Term Capital Transaction Poised to Bolster Liquidity Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program. "The growing strength of our BOT/BAL data across multiple hard-to-treat cancers reinforces our conviction in its transformative potential and
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/903911751. About Agenus Agenu
Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program. "In line with our strategic objectives, we significantly reduced our annualized operational burn rate. We anticipate further reducing our annual burn to an annualized rate of approximately $50 million by mid-2025 through the externalization of development costs associated with BOT/BAL, monetization of our CMC assets, and other reductions in operati
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 11th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/886193189.
Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. "BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where previous treatments have fallen short," said Garo Armen, Ph.D., Chairman and CEO of Agenus. "Its potential extends beyond this challenging cancer type, with promising efficacy seen in the neoadjuvant setting and other hard-to-treat cancers. While we are excited by
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 12th, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/932317413. About A
Robust Phase 2 Data Validate Consistent Clinical Activity of BOT/BAL in Metastatic MSS CRC Maturing Data Across BOT/BAL Program Demonstrate Broad Solid Tumor Activity in the Late Stage, First-Line with Chemo Combinations, and Neoadjuvant disease Commenced Interactions with Global Regulatory Authorities for BOT/BAL Approval Pathways Data from ESMO GI Demonstrate Pathologic Complete Responses with BOT/BAL Therapy in Neoadjuvant CRC Patients Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the second quarter of 2024. "Agenus milest
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti